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linical research is undergoing significant changes due to both technological ad-
vances and new visions about clinical research by the NIH and PCORI, two 
major funders of health related research. An often quoted statistic is that on 
average new discoveries have taken 17 years to make their way into common practice. 
All acknowledge this is far too long. Both NIH and PCORI recently have created and 
funded large programs aimed at doing clinical research better and more efficiently so 
that discoveries are brought to patient care and improve the health of the public more 
rapidly. In 2006 and 2007 we provided initial information about the status of the long 
standing General Clinical Research Center (GCRC) program supported by NIH for 
over 40 years and the then newly launched Clinical and Translational Science Award 
(CTSA) program designed to subsume and replace the GCRC program (Barohn, 2006; 
Barohn and Aaronson, 2007). In this report we provide an update on these and other 
programs that are aimed at improving clinical research as we know it. 
First, we briefly discuss the CTSA 
program funded by the National Center 
for Advancing Translational Sciences 
(NCATS) at NIH and describe the current 
status of Frontiers: The Heartland Institute 
for Clinical and Translational Research, the 
CTSA program headquartered at KUMC. 
Second, we discuss the NeuroNEXT pro-
gram, a consortium program funded by 
the National Institute of Neurological 
Disorders and Stroke (NINDS), NIH, and 
for which KUMC is one of 25 funded site 
participants. Third, we discuss PCORI 
and the PCORI Clinical Data Research 
Network (CDRN) and identify several in-
dividual clinical research projects funded 
by PCORI. KUMC was awarded one of 11 
CDRNs earlier this year, one of the au-
thors of this paper (Barohn) is the princi-
pal investigator of a specific comparative 
effectiveness clinical trial also funded by 
PCORI earlier this year, and KUMC in-
vestigators have been successful in ob-
taining additional clinical research grants 
from PCORI. 
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The Clinical and Translational Sci-
ence Award (CTSA) Program 
The CTSA program is a signature program 
of NIH (https://www.ctsacentral.org). With a 
budget of $475M annually it is the largest 
single program funded by NIH. Initially 
established under the former National 
Center for Research Resources, as identi-
fied above, it is now managed by the new 
National Center for Advancing Transla-
tional Science (NCATS).  
When first launched, the purpose of 
the CTSA program was to establish a 
transformative and integrated academic 
home for clinical and translational sci-
ence. Each site was required to have a 
number of key function areas or cores 
and was allowed to propose unique 
novel methods programs drawing on 
strengths of the applicant organization. 
Funding formulas varied over the years 
since 2006 when the first CTSAs were 
funded. Frontiers: The Heartland Institute 
for Clinical and Translational Research was 
funded in June 2011 for $20M over five 
years and became part of what is now a 
62 site national consortium.  
Frontiers: The Heartland Institute 
for Clinical and Translational Research. 
The Frontiers program, headquartered at 
KUMC, is a regional program 
(http://frontiersresearch.org). From its in-
ception we were committed to advancing 
aspirations of making the Kansas City 
area a major hub for life sciences re-
search. We reached out beyond KUMC 
and the University of Kansas Hospital to 
the other local academic health centers 
and their affiliated hospitals. Today, five 
academic institutions (KUMC, KU-Law-
rence, KUMC-Wichita, UMKC, and 
KCUMB) and 10 health care institutions 
(see Table 1) comprise the Frontiers pro-
gram. Investigators from all of these sites 
are eligible to apply for and use Frontiers 
resources.  
Among the successful programs un-
der the Frontiers umbrella is a pilot study 
funding program. It is increasingly com-
petitive to obtain extra-mural funding for 
research and having solid, supportive 
data from a pilot study has become essen-
tial for success with such funding. Since 
our initial funding in 2011, we have had 
four annual rounds of Requests for Pro-
posals. Across these four years, we re-
ceived 294 applications and funded 71 
projects to investigators from Children’s 
Mercy Hospital, KU-Lawrence, KU-
Wichita, UMKC, and St. Luke’s Health 
System, in addition to investigators from 
KUMC. Pilot study funding for a project 
has varied from $20-30K for each project. 
Academic partners Health system partners 
University of Kansas Medical Center - Kansas 
City 
University of Kansas Medical Center - Wichita 
University of Kansas - Lawrence 
University of Missouri-Kansas City 
Kansas City University of Medicine  
and Biosciences 
The University of Kansas Hospital, Kansas City, KS. 
Wesley Medical Center, Wichita 
Via Christi Health, Wichita 
Veterans Administration Medical Center, Kansas City 
St. Luke's Health System, KS and MO 
Children's Mercy Hospitals and Clinics KS and MO 
Truman Medical Center, Kansas City, MO. 
Swope Health Services, Kansas City, MO. 
Center for Behavioral Medicine, Kansas City, MO. 
Center for Practical Bioethics 
Table 1. The Frontiers network of academic and health-delivery institutions 
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For the Frontiers pilot study pro-
gram we have used reviewers from 
across all Frontiers sites and have invited 
other units and programs that have pilot 
study funding to award to join our pro-
cess for review and funding decisions. 
Each year we have modified our process 
in response to past years’ experience. We 
now use an approach where the peer re-
views of applications are taken to a fund-
ing council composed of representatives 
from the Frontiers sites and from other 
programs/units with pilot study funding 
to award. Combining the review and 
funding decisions of several programs 
has enhanced efficiency, reduced redun-
dancy, and extended awareness and 
knowledge of the breadth of clinical and 
translational research across our institu-
tions. The investment in these pilot stud-
ies has been substantial. For the 71 pro-
jects funded so far, $1.1M came from the 
CTSA grant and $685K was contributed 
as ‘cost-shared’ funds from other pro-
grams (the KUMC Research Institute, the 
K-INBRE program, an American Cancer 
Society grant program at KUMC, the 
KUMC Diabetes Center and departments 
of internal medicine, neurology, and 
physical therapy & rehabilitation sci-
ences, KU-Wichita, UMKC, and Chil-
dren’s Mercy Hospital.) 
While some of these pilot studies 
were recently funded and are currently 
ongoing, we already have seen substan-
tial return on the investment of pilot 
study funding. Two R01s have been 
awarded by NIH to investigators for pro-
jects based on their pilot study work and 
one other pilot study recipient anticipates 
receiving funding for an R01 this fall. In 
addition, one NIH R03 has been awarded 
to an investigator who received Frontiers 
pilot study funding for preliminary work 
and one large PCORI grant has been 
awarded to another Frontiers pilot study 
recipient. These four funded projects 
amount to over $3.2M in extra-mural re-
search funding. 
In 2013 the Frontiers program 
launched another program to provide a 
smaller amount of funding on a more 
flexible basis than the annual call for the 
formal pilot study program. Dubbed the 
Trail Blazer program, this opportunity al-
lows for obtaining that last bit of data 
needed for a competitive extra-mural re-
search grant application or for an oppor-
tunity to capitalize on an existing funded 
project and extend its work toward an ad-
ditional area of inquiry. These applica-
tions may be submitted at any time and 
undergo an administrative review. While 
applicants may ask for up to $5K, often 
less is requested or awarded. In its first 18 
months, 45 applications were received for 
Trail Blazer awards and 33 were funded 
for a total investment of just over $88K. 
All Trail Blazer recipients commit to sub-
mitting an extra-mural grant application 
within 12 months. While it is still too 
early to see return on our investment in 
these Trail Blazer awards, two recipients 
used their Trail Blazer funding to extend 
work on their active NIH R01 grants. 
Another major component of all 
CTSAs is education to train the next gen-
eration of the clinical and translational 
workforce. To this end, the Frontiers pro-
gram established a Clinical and Transla-
tional Education Center (CTREC) to coor-
dinate and manage several specific train-
ing programs. The CTREC currently of-
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fers a pre-doctoral clinical research train-
ing program (TL1), a post-doctoral men-
tored clinical research scholar program 
(KL2), and a post-doctoral fellows and 
junior faculty Clinical Research Curricu-
lum Program. Trainees in each of these 
programs may complete a formal Mas-
ters in Clinical Research degree (MS-CR). 
The Clinical Research Curriculum Pro-
gram primarily provides tuition assis-
tance so that these post-doctoral fellows 
and junior faculty may take classes re-
quired for the MS-CR degree. Tuition 
costs also are covered for the TL1 trainees 
and the KL2 Scholars. 
The TL1 program is a year-long pro-
gram that provides institutional support 
to students in clinical doctoral programs 
who are seeking a practical introduction 
to clinical and translational research. Stu-
dents selected for the TL1 program take 
this year out of their regular degree pro-
gram, thus extending their training by 
one year. The Frontiers TL1 program has 
supported four students each year from 
the KU Schools of Medicine and Phar-
macy, and from KCUMB.  
The KL2 program offers institutional 
support for mentored career develop-
ment of investigators who have recently 
completed professional training and are 
beginning a career in translational and/or 
clinical research. It is generally a two-
year program that involves a 75% time 
commitment with salary largely covered 
by the Frontiers CTSA grant. Commit-
ments from the scholars’ home depart-
ments were obtained to cover up to 25% 
salary so that each scholar would have 
the requisite 75% dedicated time for their 
research training and experience. This 
cost-sharing allowed us to support six 
KL2 Scholars in each of the two cohorts of 
Scholars thus far. While the second co-
hort only recently started their training, 
two of the first six Scholars already have 
garnered independent funding for their 
research—one was awarded an R01from 
the National Cancer Institute at NIH and 
the other received a Blue KC Health Out-
comes Grant. 
The Frontiers program also provides 
other resources to support investigators. 
While we are not describing all of these in 
this paper, it is worth noting that Fron-
tiers serves as a matchmaker for finding 
colleagues or mentors and provides a fo-
rum in which investigators may brain-
storm their research ideas or get specific 
feedback on developing grant applica-
tions. This has shown to be a very valued 
resource. In the words of one investiga-
tor, recently funded by NIH for an R01, 
and who did not receive any specific 
funding assistance from Frontiers but did 
take advantage of our collegial assis-
tance: “I can’t sing the praises of the 
CTSA enough for the help it provided to 
us.”  
Network for Excellence in Neuro-
science Clinical Trials (NeuroNEXT) 
While the CTSA program is “disease 
agnostic”, some of the categorical insti-
tutes at NIH have established national 
consortia specific to their institute’s focus 
areas. NeuroNEXT is one such consortium 
or network supported by the National In-
stitute of Neurological Disorders and Stroke 
(NINDS) (http://www.neuronext.org). It 
was created to expand the capability to 
conduct clinical studies in neuroscience. 
One of the authors of this paper (Barohn) 
is the principal investigator of the Neu-
roNEXT program at KUMC and chairs a 
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formal CTSA/NeuroNEXT committee to 
promote synergy between these two pro-
grams. 
The goals of NeuroNEXT are four-
fold. The first goal is to test promising 
therapeutics in Phase II clinical trials, us-
ing biomarkers when available, and to 
generate results that may support mov-
ing forward with a larger Phase III trial 
using a Go/No-Go decision process. The 
second goal is to accelerate drug develop-
ment through an established clinical tri-
als infrastructure. In addition to funding 
the 25 sites that comprise the NeuroN-
EXT network, NINDS also funded a Clin-
ical Coordinating Center at Mass General 
Hospital and a Data Coordinating Center 
at the University of Iowa to provide this 
clinical trial infrastructure. Through 
these entities, the NeuroNEXT network 
has the flexibility to take advantage of op-
portunities that emerge and to foster 
sharing of expertise in different diseases 
across the 25 network sites.  
The third goal of the NeuroNEXT 
program is to decrease the cost of con-
ducting trials and the time between trial 
design and trial completion. Two mecha-
nisms that support this goal are the use of 
a central IRB and standard master trial 
agreements for all studies conducted 
through the NeuroNEXT program at the 
25 sites in the network. The fourth goal is 
to coordinate efforts between the public 
and private sector and test the best thera-
peutics coming from both academic and 
industry investigators. To this end, 
NINDS leverages their existing relation-
ships with academic investigators, indus-
try investigators, and patient advocacy 
groups (Kearney, et al., 2014). 
Through the NeuroNEXT program, 
KUMC is currently involved with four 
studies. These studies focus on four dis-
eases. The first involves looking at bi-
omarkers in spinal muscular atrophy. 
The other three are intervention trials in-
volving multiple sclerosis, myasthenia 
gravis and stroke.  
The PCORI Clinical Data Research 
Network (CDRN) 
The Patient-Centered Outcomes Re-
search Institute (PCORI) was established 
as part of the federal Affordable Care Act 
and authorized by Congress to fund and 
disseminate research on the best evidence 
available for patients and health care pro-
viders to make the best decisions about 
health care. It has a very substantial 
budget and has become a major player in 
the clinical research arena. One large pro-
gram launched by PCORI is the PCOR-
net. The PCORnet is composed of both a 
clinical data research network (CDRN) 
and a patient powered research network. 
In this paper we address the CDRN pro-
gram. 
In January 2014, KUMC signed a 
$7M contract with PCORI for the 18 
month Phase 1 part of PCORnet as one of 
11 funded CDRNs (R Waitman, KUMC, 
PI). Called The Greater Plains Collaborative 
(GPC), our CDRN involves seven states 
and 10 institutions (see Table 2) from 
Minnesota to Texas—all of which are 
home to the greater prairie chicken, our 
namesake and mascot. Nine of our 10 
sites also are part of a local CTSA pro-
gram. While some other CDRNs are at in-
stitutions with CTSAs, we believe the 
GPC has done the most to integrate and 
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create synergy between these two large 
national programs. 
The overall goal of PCORnet is “to 
improve the nation’s capacity to conduct 
clinical research by creating a large, 
highly representative national patient-
centered network that supports more ef-
ficient clinical trials and observational 
studies” (http://www.pcori.org). A key 
concern for PCORI is involvement of pa-
tients and other stakeholders in all phases 
of clinical research involving people—
from idea conception to study design and 
implementation, data analyses and inter-
pretation, and dissemination and imple-
mentation of treatments shown to be 
most efficacious. This is based in the 
PCORI commitment to supporting re-
search “that will be useful to patients and 
other clinical decision makers by ensur-
ing that their questions and concerns are 
the focus of our work.” (Selby, et al, 2013). 
The specific role of the CDRN pro-
gram in PCORnet is to harness the rich 
data currently residing in electronic 
health records (EHRs). The GPC views 
the CDRN program as a test of the na-
tion’s multi-billion dollar investment in 
EHRs. While EHRs are increasingly pre-
sent in hospitals and health care prac-
tices, there has been little quantitative ev-
idence for determining the degree to 
which EHR data can be used to assess 
clinical effectiveness. Given the diversity 
of EHRs, there also are many challenges 
to establishing the interoperability and 
common language standards needed to 
conduct research across institutions us-
ing different EHRs. Technical issues in-
volved in establishing the GPC and 
working with our 10 sites are discussed 
elsewhere (Waitman, et al., 2014).  
While it is too soon to have any spe-
cific outcomes from the GPC to discuss 
here, we do want to identify that the GPC 
will be working within the PCORnet on 
three specific conditions. All applicants 
for a CDRN were required to select one 
common condition, one rare disease, and 
to agree to work on obesity as an all-
CDRN focus area. After consulting with 
our community stake-holders through 
our respective CTSA community engage-
ment core function areas, the GPC se-
lected breast cancer as our common con-
dition. For our rare disease we selected 
amyotrophic lateral sclerosis (ALS), com-
monly known as Lou Gehrig’s disease, 
State Medical Center 
Kansas 
Missouri 
Iowa 
Wisconsin 
 
 
Minnesota 
Nebraska 
Texas 
 
University of Kansas Medical Center 
Children’s Mercy Hospital 
University of Iowa Healthcare 
University of Wisconsin-Madison 
Medical College of Wisconsin 
Marshfield Clinic 
University of Minnesota Academic Health Center 
University of Nebraska Medical Center 
University of Texas Health Sciences Center at San Antonio 
University of Texas Southwestern Medical Center 
Table 2.The Greater Plains Collaborative (GPC) is a network of 10 leading medical centers in 
seven states. 
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because of the expertise we have in this 
specific rare disease. 
Last, we introduce two independent 
projects recently funded by PCORI to illus-
trate the types of research that PCORI sup-
ports. Patient Assisted Intervention for 
Neuropathy: Comparison of Treatment in 
Real Life Situations (PAIN-CONTRoLS – R 
Barohn, PI) is comparing four different 
drugs used to treat neuropathic pain to see 
which is most effective. The other study, 
Smoking Cessation Versus Long-Term 
Nicotine Replacement among High-Risk 
Smokers (E Ellerbeck, PI) is comparing two 
different methods for smoking cessation in 
patients with chronic obstructive pulmo-
nary disease (COPD.) Both studies are on-
going and both actively sought input and 
involvement of patients in designing the 
studies—resulting in changes and addi-
tions that made the studies more relevant 
to the patients affected by these conditions. 
These are just two examples of how this 
new funding resource is allowing our in-
vestigators to conduct practical compara-
tive effectiveness studies in our region and 
to do so in partnership with the people 
whose health we hope to improve.  
In sum, collectively, the CTSA pro-
gram, the institute-specific research net-
works like the NeuroNEXT program, and 
PCORI for both its ambitious PCORNet 
program and its general portfolio of sup-
ported health outcomes research are driv-
ing a new frontier in clinical research. Cen-
tral to this new frontier is collaboration 
across disciplines and institutions, within 
and outside academia, with industry and 
the public sector, including patients, advo-
cates, and policy makers. The shared hope 
is that through such collaboration we can 
more rapidly and more rigorously find an-
swers to the questions that matter most for 
achieving a healthier public.  
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